

PRESS RELEASE

**Marie-Claire Janailhac-Fritsch appointed Chairman of the
Guerbet Board of Directors**

Villepinte, 30 September 2013

The Board of Directors of Guerbet, an international pharmaceutical group specialized in medical imaging, has unanimously decided to appoint Marie-Claire Janailhac-Fritsch as its chairman. The appointment takes effect immediately.

Marie-Claire Janailhac-Fritsch thus takes over from Jean-Jacques Bertrand, who had been chairman of the Board of Directors since May 2006. Jean-Jacques Bertrand resigns his position as chairman but remains on the Guerbet Board of Directors.

“I am very happy to hand over to Marie-Claire Janailhac-Fritsch, a member of the Guerbet Board since May 2011, in a spirit of continuity. Her acknowledged experience in the pharmaceutical industry and in the development of innovative molecules for the cosmetics market will be a considerable asset in accompanying Guerbet in its strategic dynamic, conjugating performance, quality and sustainable development on the expanding medical imaging market”, Mr. Bertrand explained.

Mrs. Janailhac-Fritsch commented “I would like to thank the Board for having appointed me to this position and join with my fellow Board directors in paying tribute to the achievements of Jean-Jacques Bertrand. I have confidence in all the Group’s teams, under the leadership of Yves L’Epine, in pursuing its expansion. I know that the Board can count on their commitment in proposing contrast agents, medical devices and innovative solutions indispensable to diagnostic and interventional imaging to health professionals to enhance patient prognosis and quality of life”.

A graduate of the prestigious Hautes Etudes Commerciales (H.E.C) business school (1978), Marie-Claire Janailhac-Fritsch has over thirty years’ professional experience, including ten years in the pharmaceutical industry – from 1978 à 1987 – with Eurorga and Smith Kline. She is a consultant for the cosmetics industry and a member of the French Institute of Directors (IFA).

Since 1987 Marie-Claire Janailhac-Fritsch has worked in the cosmetics industry and has created several startups – having developed particularly innovative molecules in the cosmetics sector – which she chaired before selling them to a Canadian chemicals and pharmaceuticals group.

Guerbet's Board of Directors has nine members:

- Marie-Claire Janailhac-Fritsch, Chairman
- Marion Barbier
- Jean-Jacques Bertrand
- Jacques Biot
- Vincent Dagommer
- Olivier Guerbet
- Yves L'Epine
- Christian Louvet
- Claire Massiot-Jouault

About Guerbet

A pioneer in the field of contrast agents with more than 80 years of experience, Guerbet is the only pharmaceutical group fully dedicated to medical imaging worldwide. As such it has a complete offering of contrast agents for X-ray, MRI and interventional radiology, along with a range of injectors and related medical devices to provide improved patient diagnosis and treatment.

To promote the discovery of new products and ensure its future growth, Guerbet devotes significant resources to research and development every year (approximately 10% of sales). Guerbet (GBT) is listed on NYSE Euronext Paris (Eurolist Compartment B – Mid Caps) and had sales of € 403 million in 2012 with a total workforce of 1,400 employees including 1,000 in France.

Guerbet is a member of G5 Health, an industry association of major French health and life sciences companies.

For additional information about Guerbet please go to www.guerbet.com

Press contacts:

Anne-Laure Delasalle, Communications Director

Tel. : + 33 (0)1 45 91 50 03

anne-laure.delasalle@guerbet-group.com

Guillaume de Chamisso, PrPa agency

Tel : + 33 (0)1 46 99 69 69 - + 33 (0)6 28 79 00 61

guillaume.dechamisso@prpa.fr